Tam Vincent H, Ledesma Kimberly R, Schilling Amy N, Lim Tze-Peng, Yuan Zhe, Ghose Romi, Lewis Russell E
University of Houston College of Pharmacy, Houston, TX 77030, USA.
Diagn Microbiol Infect Dis. 2009 Aug;64(4):427-33. doi: 10.1016/j.diagmicrobio.2009.03.031.
We have previously demonstrated Pseudomonas aeruginosa resistance selection because of suboptimal carbapenem exposures in an in vitro infection model, but the in vivo relevance of the observations is not well established. In this study, we examined the impact of carbapenem exposures on resistance selection using a neutropenic murine pneumonia model. Neutropenic mice were infected with approximately 10(6) CFU of P. aeruginosa intratracheally. Ten animals each were treated with 400 or 50 mg/kg of meropenem intraperitoneally or placebo every 8 h, given 2 h after infection for 2 to 4 days. Quantitative assessment of bacterial burden in lung tissues was performed at baseline, upon death, or at the end of experiment. Meropenem (400 mg/kg) offered a significant survival benefit, but selective amplification of the OprD(-) mutant population in lung tissue was observed in 20% to 30% of the animals. Our data suggested that suboptimal meropenem exposures might facilitate in vivo selection of resistance in a heterogeneous P. aeruginosa population.
我们之前在体外感染模型中证明了由于碳青霉烯类药物暴露不足导致铜绿假单胞菌耐药性的选择,但这些观察结果在体内的相关性尚未得到充分证实。在本研究中,我们使用中性粒细胞减少的小鼠肺炎模型研究了碳青霉烯类药物暴露对耐药性选择的影响。中性粒细胞减少的小鼠经气管内感染约10(6) CFU的铜绿假单胞菌。每组10只动物,每8小时腹腔注射400或50 mg/kg美罗培南或安慰剂,在感染后2小时给药,持续2至4天。在基线、死亡时或实验结束时对肺组织中的细菌载量进行定量评估。美罗培南(400 mg/kg)提供了显著的生存益处,但在20%至30%的动物中观察到肺组织中OprD(-)突变群体的选择性扩增。我们的数据表明,美罗培南暴露不足可能会促进体内异质性铜绿假单胞菌群体耐药性的选择。